Skip to main content

Cannabis Testing Market Analysis in Europe to 2025 - SCIEX, Merck KGaA, Restek Corporation, Waters, CannaSafe Analytics

Press release   •   Apr 17, 2019 13:08 IST

Cannabis Testing Market

Cannabis provides the unique opportunities in Macedonia, where the medical system is in a stage of evolution and modernization. Local medical specialists are now able to prescribe cannabis in the country. Considering this, Macedonian cannabis promoters worked with local governments and created the medical cannabis training program in an effort to support doctors and their patients. Currently, the impetus of the Macedonian medical cannabis movement is moving quickly, and the public opinion on cannabis has also changed dramatically in the region.

The growing number of countries are adopting medical cannabis laws but the governmental officials are rare that encouraging healthcare professionals to become educated about cannabis plant medicines. On the use of cannabis in clinical practice, to instruct local healthcare providers, various cannabis experts were invited to Macedonia, in 2016. The program was held in Skopje and was supported and funded by the Macedonian Ministry of Health.

Europe Cannabis Testing Market to 2025 - Regional Analysis and Forecasts by Type (Products and Software); Services (Potency Testing, Terpene Profiling, Pesticide Screening, Residual Solvent Screening, Heavy Metal Testing, Microbial Analysis, and Genetic Testing); End User (Testing Laboratories, Drug Manufacturers, and Research Institutes) and Country

Get Sample Copy at

With the legalization of cannabis in Europe, producers are increasingly looking for quick and accurate means of determining the quality and potency of their products. Factors such as, increasing use of cannabis, proportionally rises the demand for cannabis testing that influence the research activities in the region. The European Parliament is calling for an EU-wide policy for medical cannabis and properly funded scientific research. To achieve this, in February 2019, members of the European Parliament (MEPs) adopted a resolution on the use of cannabis for medicinal purposes. Many European countries have legalized the medical use of cannabis or cannabinoids or are considering changes to their legislation. The main purpose of the resolution is to draw a clear distinction between medical cannabis and other uses of cannabis.

However, no EU country authorizes the smoking or home-growing of cannabis for medical purposes. While the World Health Organization (WHO) has officially recommended that the cannabis compound cannabidiol (CBD) should not be classified as a controlled substance. Although, at the present time, there are no EU-wide rules for either the medical or recreational use of cannabis in the region.

The cannabis or cannabinoids have therapeutic effects in stimulating appetite and in alleviating the symptoms of, for instance, mental disorders or epilepsy, asthma, cancer and Alzheimer’s. However, more research is needed. The main purpose of the MEPs to address research gaps on medical cannabis in the region and call on member states to seize the potential of cannabis-based medicines.

Thus, the need for more research in the therapeutic area and stimulate innovation with regard to medicinal cannabis projects is expected to witness rapid growth in the region.

Browse Complete Report at

Contact us –

Contact Person : Sameer Joshi

Phone : +1-646-491-9876

Email Id :


The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Media, Healthcare and Telecommunication industries.

Comments (0)

Add comment


By submitting the comment you agree that your personal data will be processed according to Mynewsdesk's Privacy Policy.